IQVIA Holdings Inc. $IQV Stake Lowered by AlphaQuest LLC

AlphaQuest LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 62.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,050 shares of the medical research company’s stock after selling 8,299 shares during the quarter. AlphaQuest LLC’s holdings in IQVIA were worth $796,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd grew its holdings in shares of IQVIA by 44.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 807 shares of the medical research company’s stock valued at $127,000 after purchasing an additional 249 shares during the last quarter. Asset Management One Co. Ltd. grew its holdings in IQVIA by 0.5% in the 2nd quarter. Asset Management One Co. Ltd. now owns 74,107 shares of the medical research company’s stock worth $11,679,000 after buying an additional 395 shares in the last quarter. AlTi Global Inc. grew its holdings in IQVIA by 124.6% in the 2nd quarter. AlTi Global Inc. now owns 6,591 shares of the medical research company’s stock worth $1,067,000 after buying an additional 3,656 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in IQVIA by 36.5% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 7,327 shares of the medical research company’s stock worth $1,155,000 after buying an additional 1,958 shares in the last quarter. Finally, Ethic Inc. grew its holdings in IQVIA by 39.8% in the 2nd quarter. Ethic Inc. now owns 33,391 shares of the medical research company’s stock worth $5,258,000 after buying an additional 9,498 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on IQV shares. Robert W. Baird increased their price objective on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Truist Financial increased their price objective on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Mizuho increased their price objective on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. UBS Group increased their price objective on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Stock Performance

IQV opened at $220.64 on Monday. The firm has a market cap of $37.51 billion, a PE ratio of 31.93, a P/E/G ratio of 2.42 and a beta of 1.32. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The business has a fifty day simple moving average of $194.47 and a 200-day simple moving average of $171.56. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $225.91.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.